Executive summary
Many women in perimenopause and menopause wait too long for correct diagnosis and treatment. Symptoms are often misattributed, care is inconsistent, and providers do not always have enough menopause-specific training or decision support.
Pause-Health.ai is designed to close that gap. The product supports providers at the point of care with clear risk scoring, treatment suggestions, and workflow-ready guidance. The goal is better outcomes for patients and measurable operational value for health systems and payers.
Target outcomes
- Reach approximately 89% diagnostic accuracy in validation settings.
- Reduce diagnosis timelines from a 2.5-year baseline to roughly 6-12 months.
- Lower avoidable healthcare spend, currently estimated at about $1,685 per patient due to delays and misdiagnosis.
- Improve symptom-to-treatment matching across common menopause symptom clusters.
Why this matters
Menopause affects a very large population in the U.S., but care quality is still uneven:
- Around 50 million women are affected.
- About 67% of perimenopausal women are initially misdiagnosed.
- Average time to correct diagnosis is approximately 2.5 years.
- Many PCPs report very limited menopause-specific training.
This creates preventable costs and quality issues for patients, providers, and payers alike.
What Pause-Health.ai provides
- AI-assisted diagnostic scoring and risk stratification.
- Personalized treatment pathway recommendations.
- Real-time guidance embedded in EHR workflows.
- Outcomes and ROI tracking for provider and payer stakeholders.
Technology foundation
The platform uses open-source healthcare infrastructure:
- JupyterHealth Exchange for consented FHIR R5 data exchange.
- Digital Biomarker Discovery Pipeline (dbdp) for wearable-derived signals — sleep, HRV, activity, and skin temperature.
Business model
Pause-Health.ai is a B2B healthcare SaaS company with three primary revenue channels:
- Health systems: $25K-$75K annual contracts.
- Payers: $0.50-$2.00 PMPM for eligible populations.
- Medical practices: $2K-$8K annual subscriptions.
Revenue targets
- $8M ARR within 24 months.
- $50M+ ARR by year 4.
Market and strategic timing
- U.S. menopause market estimated at $15.4B, growing approximately 5.7% annually.
- Health systems and payers are under pressure to improve outcomes and reduce waste.
- AI capabilities are now practical enough for real-time, point-of-care support.
- FHIR and biomarker tooling reduce time to implementation and validation.
Core problems to solve
1. Misdiagnosis and delays
- Symptoms are often dismissed or mislabeled.
- Correct diagnosis can take years.
- Delays reduce trust and prolong patient suffering.
2. Cost burden
- Excess referrals and avoidable utilization increase costs.
- Payers and providers both absorb inefficiency.
- Productivity losses impact patients and employers.
3. Inconsistent treatment
- No universal protocol across systems.
- Recommendations vary widely between providers.
- Feedback loops for learning are often missing.
4. Provider workflow burden
- Menopause care crosses specialties and is hard to manage in short visits.
- Research evolves faster than busy clinicians can track.
- Existing tools are often not integrated into daily workflows.
24-month objectives
Primary objective
Deploy AI decision support across 25 health systems, improve diagnostic accuracy by 30%, cut time-to-diagnosis by 50%, and reach $8M ARR.
Strategic objectives
- Clinical validation: Validate performance and publish evidence.
- Health system adoption: Win anchor customers and prove operational ROI.
- Payer scale: Sign regional partnerships and demonstrate PMPM savings.
- Revenue validation: Build durable ARR and expansion metrics.
- Product excellence: Deliver robust EHR integration, performance, uptime, compliance, and regulatory progress.
Success criteria by month 24
- 89%+ diagnostic accuracy in validation programs.
- 50%+ reduction in time-to-diagnosis.
- $8M+ ARR with a credible path to $50M ARR.
- 20+ health system customers and 2+ payer partnerships.
- Strong provider adoption, NPS, and enterprise trust posture.
Strategic priorities
- Lead with clinical evidence.
- Build around provider workflow realities.
- Align value metrics with payer economics.
- Continuously improve from real-world outcome data.
- Treat compliance, safety, and trust as long-term differentiation.
Part 2: deeper dives
The full Part 2 of this brief is published as a set of interlinked sections. Each covers one workstream in depth.
- Customer selection — health system and payer ICPs.
- Customer insights — provider and patient interview synthesis.
- Data inventory and strategy — sources, strategy, and moats.
- Competition — landscape and positioning.
- Digital strategy — architecture, motion, and moats.
- Technology choices — stack, AI approach, and safety.